Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Gothenburg, January 17, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company's Chief Scientific Officer and co-founder, Professor Magnus Essand, has received a prestigious speaking invitation from the Eighth International Cancer Immunotherapy Conference (CICON).

CICON is the world's largest recurring conference in the field of cancer immunotherapy and is being held this year in Washington, DC, between September 8 and 11.

"The fact that our co-founder and Chief Scientific Officer Magnus Essand has been invited as a speaker at the world's largest cancer immunotherapy conference, CICON, underlines the quality and level of innovation in Elicera Therapeutics' research platform. We are already looking forward to the opportunity to present our unique CAR T-cell therapies to a broad and initiated international audience in the US later this year,” said Jamal El-Mosleh, CEO of Elicera Therapeutics.

In his presentation, Magnus Essand will focus on the company's CAR T-cell programs ELC-301 and ELC-401, which are being developed for the treatment of diffuse large B-cell lymphoma and glioblastoma, respectively. Both programs use Elicera's unique iTANK technology platform to strengthen and broaden the effect of the treatments and reduce the risk of disease recurrence.